QLS31904
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 10, 2022
QLS31904-101: Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=290 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Monotherapy • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3
July 18, 2022
Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=290 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
Monotherapy • New P1 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3
1 to 2
Of
2
Go to page
1